4D Molecular Therapeutics (FDMT) Amortization of Deferred Charges (2021 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Amortization of Deferred Charges of $786000.0 for Q1 2026, up 11.81% year-over-year from $703000.0 in Q1 2025, and up 2.88% quarter-over-quarter from $764000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Amortization of Deferred Charges for 6 consecutive years, with $786000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 11.81% year-over-year to $786000.0; the TTM figure through Mar 2026 stood at $3.0 million (up 29.13% YoY), while the FY2025 annual figure was $2.9 million, up 42.84% from the prior year.
- Amortization of Deferred Charges grew to $786000.0 in Q1 2026 per FDMT's latest filing, from $764000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $786000.0 in Q1 2026 and bottomed at $349000.0 in Q2 2023.
- Historically, Amortization of Deferred Charges has averaged $517117.6 across 5 years, with a median of $421000.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges slipped 4.74% — and 2025, when it soared 67.91%.
- 4D Molecular Therapeutics' Amortization of Deferred Charges stood at $374000.0 in 2022, then grew by 9.89% to $411000.0 in 2023, then jumped by 67.4% to $688000.0 in 2024, then gained by 11.05% to $764000.0 in 2025, then rose by 2.88% to $786000.0 in 2026.
- Business Quant data shows FDMT's Amortization of Deferred Charges at $786000.0 in Q1 2026, $764000.0 in Q4 2025, and $742000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 809,000.00 |
| Jun 30, 2026 | 809,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Mar 31, 2026 | 786,000.00 |
| Dec 31, 2025 | 764,000.00 |
| Dec 31, 2025 | 764,000.00 |
| Sep 30, 2025 | 742,000.00 |
| Sep 30, 2025 | 742,000.00 |
| Jun 30, 2025 | 722,000.00 |
| Jun 30, 2025 | 722,000.00 |
| Mar 31, 2025 | 703,000.00 |
| Mar 31, 2025 | 703,000.00 |
| Dec 31, 2024 | 688,000.00 |
| Dec 31, 2024 | 688,000.00 |
| Sep 30, 2024 | 513,000.00 |
| Sep 30, 2024 | 513,000.00 |
| Jun 30, 2024 | 430,000.00 |
| Jun 30, 2024 | 430,000.00 |
| Mar 31, 2024 | 421,000.00 |
| Mar 31, 2024 | 421,000.00 |